Subtype
Pancreatic Neoplasm
CI-CAN-00001356Explore in graph →
Non-malignant987 active trials8 approved drugs63 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001356Explore in graph →
Clinical trials
4,216 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06464965 | Clinical Study of Cord Blood-Derived CAR-NK Cells in Gastric Cancer and Pancreatic Cancer | completed | Phase 1 | 9 | Zhejiang Provincial People's HospitalOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT00113360 | RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma | completed | Phase 2 | 67 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT04106856 | Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Pancreatic Cancer(SHAPER) | completed | Phase 1 | 22 | University of UtahOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT03310632 | Determine Function of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 55 | Golden Biotechnology CorporationINDUSTRY | 3 | Jul 2, 2026 | clinicaltrials |
| NCT06050395 | The MONITOR Study: Remote Monitoring Of a Nutrition Intervention To Optimize Treatment Response | completed | N/A | 40 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT04483726 | Distal Pancreatectomy, Minimally Invasive or Open, for Malignancy (DIPLOMA)(DIPLOMA) | completed | N/A | 9 | University Hospital, MontpellierOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT05708950 | A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) | completed | Phase 1 / Phase 2 | 40 | Kineta Inc.INDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT01821729 | Radiation w/FOLFIRINOX-Losartan for Pancreatic Cancer | completed | Phase 2 | 50 | Massachusetts General HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT03269526 | BATs Treatment for Pancreatic Cancer, Phase Ib/II | completed | Phase 1 / Phase 2 | 22 | University of VirginiaOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07651020 | The Clinical Application Value of SPECT Imaging Targeting LRRC15 in Malignant Tumors | completed | — | 1 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT04774198 | Perioperative Immune Function and Clinical Complications in Pancreaduodenectomy | completed | — | 58 | Rigshospitalet, DenmarkOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT01542177 | A Study Using 18F-FAZA and PET Scans to Study Hypoxia in Pancreatic Cancer | completed | — | 48 | University Health Network, TorontoOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05630183 | A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer | completed | Phase 2 | 81 | Agenus Inc.INDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05964361 | First-in-human Interleukin-15-transpresenting Wilms' Tumor Protein 1-targeting Autologous Dendritic Cell Vaccination in Cancer Patients(IL15-TransDC) | completed | Phase 1 / Phase 2 | 10 | University Hospital, AntwerpOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT05546476 | Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15(PROACC-1) | completed | Phase 2 | 187 | PfizerINDUSTRY | 11 | Jun 3, 2026 | clinicaltrials |
| NCT06266143 | A Trial of Y101D in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 71 | Wuhan YZY Biopharma Co., Ltd.INDUSTRY | 1 | May 27, 2026 | clinicaltrials |
| NCT03095781 | Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer | completed | Phase 1 | 47 | Emory UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT02890355 | FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer | completed | Phase 2 | 123 | National Cancer Institute (NCI)NIH | 1 | May 20, 2026 | clinicaltrials |
| NCT03245346 | Effects of Epidural Anesthesia and Analgesia on the Prognosis in Patients Undergoing Pancreatic Cancer Surgery | completed | N/A | 540 | Fudan UniversityOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07592338 | Agreement Between Large Language Model-Generated Treatment Recommendations With Guideline-Based and Tumor Board Decisions in Gastrointestinal Cancer(KITuKo) | completed | — | 30 | Medizinische Hochschule Brandenburg Theodor FontaneOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT07592663 | Oncologic Safety and Lymphadenectomy in Parenchyma-Sparing Resection for SPN(PSR for SPN) | completed | — | 708 | Fudan UniversityOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT04776837 | Predicting Disease Progression and/or Recurrence in Cancer | completed | — | 159 | Massachusetts General HospitalOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT06119217 | Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients | completed | Phase 2 | 194 | Trishula Therapeutics, Inc.INDUSTRY | 7 | May 13, 2026 | clinicaltrials |
| NCT03415854 | Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)(NABPLAGEMD) | completed | Phase 2 | 34 | HonorHealth Research InstituteOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT03767582 | Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas. | completed | Phase 1 / Phase 2 | 22 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT03851237 | CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy | completed | Phase 1 | 69 | Washington University School of MedicineOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT03552718 | QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers. | completed | Phase 1 | 5 | NantBioScience, Inc.INDUSTRY | 1 | May 7, 2026 | clinicaltrials |
| NCT05111353 | Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery | completed | Phase 1 | 33 | Washington University School of MedicineOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT03797326 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | completed | Phase 2 | 611 | Merck Sharp & Dohme LLCINDUSTRY | 17 | May 4, 2026 | clinicaltrials |
| NCT05014776 | Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer | completed | Phase 2 | 17 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT05535894 | Endoscopic Radiofrequency Ablation of Celiac Ganglion for Pain Management and Improvement of Quality of Life in Patients With Unresectable Pancreatic Cancer | completed | — | 19 | West Virginia UniversityOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT05085548 | ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies | completed | Phase 1 | 46 | ProDa BioTech, LLCINDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT00885066 | Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer | completed | Phase 1 | 30 | Centre Antoine LacassagneOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT03138720 | Pre-operative Treatment for Patients With Untreated Pancreatic Cancer | completed | Phase 2 | 40 | HonorHealth Research InstituteOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT01692873 | Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors(PACAomics) | completed | N/A | 274 | Institut Paoli-CalmettesOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT07542782 | Pancreatic Resection in Fit Octogenarians With Nonmetastatic Pancreatic Cancer(PRONPaC) | completed | — | 2,048 | Medizinische Hochschule Brandenburg Theodor FontaneOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT04128332 | Pre-operative Stereotactic Ablative Body Radiotherapy Followed by Immediate Surgery for Pancreatic Cancer(PORTICO-SABR) | completed | N/A | 10 | CCTU- Cancer ThemeOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT04899739 | Intraoperative Endoscopic Ultrasound for Pancreatic Cancer(EchoSurg) | completed | N/A | 33 | IHU StrasbourgOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05247164 | EUS-guided PORtal Vein Sampling for Circulating Tumor Cells in Pancreatic Cancer Patients(EUPhORIC) | completed | N/A | 23 | IRCCS San RaffaeleOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05304936 | HCW9218 for Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 21 | ImmunityBio, Inc.INDUSTRY | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03403049 | Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer | completed | Phase 1 | 14 | Montefiore Medical CenterOTHER | 2 | Apr 13, 2026 | clinicaltrials |
| NCT05461430 | Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)(TraveraRTGx) | completed | — | 72 | Travera IncINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04241367 | Verification of Predictive Biomarkers for Pancreatic Cancer Treatment Using Multicenter Liquid Biopsy | completed | — | 420 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 9, 2026 | clinicaltrials |
| NCT06973161 | ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors | completed | — | 140 | AstraZenecaINDUSTRY | 12 | Apr 8, 2026 | clinicaltrials |
| NCT04132505 | Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer | completed | Phase 1 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07319767 | Comparing the TDTP-RECIST With RECIST 1.1 and Other Volumetric Evaluation Methods for Assessing the Therapeutic Efficacy of Irregular Malignant Tumors | completed | — | 120 | Shanghai Zhongshan HospitalOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT02077881 | Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 157 | NewLink Genetics CorporationINDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT05617872 | Vinegar-induced Collection of Duodenal Pancreatic Juice Via Endoscopic Ultrasound | completed | N/A | 75 | Peking Union Medical College HospitalOTHER | 1 | Apr 2, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jul 9, 2026source: clinicaltrials